Imaging in the Era of COVID-19 Presentation

24
Perspectum Ltd. Dr. Rajarshi Banerjee Imaging in the Era of COVID-19: Maintaining Safety Above All

Transcript of Imaging in the Era of COVID-19 Presentation

Page 1: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Dr. Rajarshi Banerjee

Imaging in the Era of COVID-19: Maintaining Safety Above All

Page 2: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Your speaker: Dr. Rajarshi Banerjee

Dr. Rajarshi Banerjee is the CEO of Perspectum, he graduated in medicine from the University of Oxford and went on to complete a Masters in Public Health at the London School of Hygiene and Tropical Medicine, before returning to Oxford, for his doctorate.

He developed multiparametric liver MRI techniques at the University of Oxford, which led to the creation of Perspectum. He is an expert on liver imaging and a consultant physician for Oxford University Hospitals NHS Foundation Trust.

Rajarshi has many years of experience in running clinical trials and working in multidisciplinary scientific teams to develop applications for cutting-edge imaging technology, and is a keen advocate of adaptive trial design.

Page 3: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Key topics to cover

Attendees are encouraged to ask questions throughout the webinar!

How the global

pandemic is impacting medical

research.

Prioritising safety for

outpatient imaging.

The impact of COVID-19 on societal well-

being and healthcare.

The growing importance of

imaging biomarkers.

Page 4: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

How the global pandemic is impacting medical researchSponsors who are actively running trials

March

April May/June

Minimize the impact on quality

data collected

Non-covid clinical research has been suspended in most academic settings

Most large pharma companies have

suspended recruitment for

non-covid research

This coincides with lockdown in most geographies

Lock down restrictions are likely

to ease in Europe

When will trials resume?

Page 5: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

How the global pandemic is impacting medical researchSponsors who are starting up studies

• Find ways to work quickly. Patients need treatments.

• Expect increased enrolment competition when trials resume.

• "Hey, we do what we do best. We improvise, all right?" - Brian O'Connor | Fast and Furious 6 (2013)

Page 6: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Setting up a study quickly & safely.A case study from COVERSCAN

Page 7: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Study set up 30 days from initiation to first patient in

Start of study protocol drafting

Submitted to the REC

REC Meeting

REC Initial Feedback

Response to REC

REC Approval

First Study Day

Page 8: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

First Study Day28 April 2020

AM

AM

AM

AM

05:00

08:30

10:30

11:00

Arrival of Alliance Medical truck(s)

Study Team on site at Gemini

ITV Meridian

First Participant

Page 9: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Study Visit FlowMaintaining safety above all

Step 1

Step 2

Page 10: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

The Alliance Medical “Kit”Maintaining safety above all

Mobile Clinical Suite and CT Scanner

Mobile MRI Scanner

Page 11: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Mobile Clinical Suite & CT Scanner

Video cred Vadim Belenov

Page 12: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Mobile MRI Scanner

Page 13: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

40 minutes scan

Page 14: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Prioritising safety for outpatient imaging

Page 15: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Prioritising safety for outpatient imagingPPE: The MaskFFP3 (European standard) respirators filter 99% of particles.

FFP2 respirators are specified to filter 94% of particles

The N99 (American standard) respirator is an alternative to the FFP3 and filters

99% of particles

An N95 respirator is specified to filter 95% of particles and is a close equivalent to the FFP2

Other equivalents:• KN95 (China)• P2 (Australia/New Zealand)• DF FFR (Japan)

The Type IIR (European Standard) fluid resistant surgical mask is the “regular” surgical mask often used in clinical settings

The Level 2 (American standard) fluid resistant surgical mask is equivalent to the Type IIR

Page 16: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Participant Operator

Prioritising safety for outpatient imagingPPE: The Mask

Type IIR/Level 2 Fluid Resistant Mask

Respirator(N95 non-valved&FFP3 valved)

Page 17: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Prioritising safety for outpatient imagingUltrasound / echocardiography

• Ultrasound transducers and cables should be cleaned and disinfected between patients. • Use only single-use gel packets.

• Technicians should wear full PPE.• Clinicians who are at increased health

risk should not perform ultrasound procedures • Comordities: Over 60, obesity, hypertension,

and diabetes (Richardson et. al., 2020)• Cardiovasuclar disease and respiratory

system disease (Yang J et. Al., 2020)

Page 18: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Prioritising safety for outpatient imagingUltrasound / echocardiography

Page 19: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Prioritising safety for outpatient imagingMRI/CT guidelines

2 3 4 5

Virtual patient check-in

Patient in waiting room

MRI/CT Scan

Deep clean the suite

15 minutesBetween patients

• Social Distancing• Low Patient Volume• Masks Provided• Replace fabric chairs

• Patient and technologist in separate rooms

• Remote activations available

• Sanitize the scanner

• Clean coils & table

Page 20: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Fatty Liver Disease is fundamental to COVID-19The underdiagnosed, asymptomatic health condition

• NAFLD is recognized as the most prevalent chronic liver disease globally, with a well documented association with obesity and metabolic syndrome.• Obesity is the biggest single chronic risk

factor for hospital admission for COVID-19 in patients under 60, increasing the risk 2-3-fold.

• Identifying high-risk patients and assessing multi-organ involvement is vital.• NASH awareness may increase as a result

"Understanding the impact of COVID-19 on specific patient populations such as those with obesity, diabetes, fatty liver disease and NASH is essential to providing actionable advice to clinicians and patients to provide optimal care and avoid needless deaths.”

- Donna Cryer, President of the Global Liver Institute

Page 21: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

The impact of COVID-19 on societal well-being and healthcare

• Best time to invest in healthcare tech is now! • Second chance at missed opportunities.

• Eli Lilly’s CEO David Ricks said the biopharma industry has a “once in a generation opportunity to reset" its reputation.

• Gilead CEO Daniel O’Day believes the pandemic will help for “innovative, research-based companies,” • The public will recognize the industry’s “ability to solve a human

crisis like this, because of the decades of investment,” he said. “The tone is different in Washington."

Page 22: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

How will COVID-19 affect future endpoints? The growing importance of imaging biomarkers

COVID-19 has highlighted the importance of non-contact, non-invasive

testing

Prior authorization for

NASH will be imaging and

bloods

Biopsy is inherently

more invasive

Now more than ever, it’s important to have

a way to diagnose NAFLD/NASH patients due to the underlying

comorbidities associated with

COVID-19.

Page 23: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Questions & Answers

Page 24: Imaging in the Era of COVID-19 Presentation

Perspectum Ltd.

Thank youTo find out more visit:

Perspectum.comTo find out more information:

Thank you

Perspectum.com

@PerspectumGroup

@perspectum.diagnostics